# Characterizing cognitive function during relapse in mul

Multiple Sclerosis Journal
20, 1745-1752
DOI: 10.1177/1352458514533229

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Cross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil. Clinical Neuropsychologist, 2015, 29, 836-846. | 1.5 | 43 |
| 2 | Impact of multiple sclerosis relapse: The NARCOMS participant perspective. Multiple Sclerosis and Related Disorders, 2015, 4, 234-240. | 0.9 | 45 |
| 3 | The meninges: new therapeutic targets for multiple sclerosis. Translational Research, 2015, 165, 255-269. | 2.2 | 65 |
| 4 | Subclinical MRI disease activity influences cognitive performance in MS patients. Multiple Sclerosis and Related Disorders, 2015, 4, 137-143. | 0.9 | 23 |
| 5 | Cognitive Impairment in Multiple Sclerosis: Clinical, Radiologic and Pathologic Insights. Brain Pathology, 2015, 25, 79-98. | 2.1 | 151 |
| 6 | Treatment of Acute Relapses in Multiple Sclerosis. , 2016, , 307-326. | | 5 |
| 7 | Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis. Canadian Journal of Neurological Sciences, 2016, 43, 33-43. | 0.3 | 13 |
| 8 | Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab. Multiple Sclerosis and Related Disorders, 2016, 10, 116-122. | 0.9 | 48 |
| 9 | Pediatric multiple sclerosis. Neurology, 2016, 87, S82-7. | 1.5 | 78 |
| 10 | Pathology and MRI: exploring cognitive impairment in MS. Acta Neurologica Scandinavica, 2016, 134, 24-33. | 1.0 | 62 |
| 11 | Differential diagnosis, discerning depression from cognition. Acta Neurologica Scandinavica, 2016, 134, 14-18. | 1.0 | 18 |
| 12 | White Matter Disorders. , 2016, , 665-684. | | 2 |
| 13 | Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 36-42. | 1.4 | 53 |
| 14 | Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis. CNS Drugs, 2016, 30, 209-225. | 2.7 | 23 |
| 15 | Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. Multiple Sclerosis Journal, 2016, 22, 659-667. | 1.4 | 107 |
| 16 | Information processing speed in multiple sclerosis: Past, present, and future. Multiple Sclerosis Journal, 2017, 23, 772-789. | 1.4 | 133 |
| 17 | Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 721-733. | 1.4 | 562 |
| 18 | Normal appearing white matter permeability: a marker of inflammation and information processing speed deficit among relapsing remitting multiple sclerosis patients. Neuroradiology, 2017, 59, 771-780. | 1.1 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial. CNS Drugs, 2017, 31, 161-168. | 2.7 | 23 |
| 21 | Signes et symptÃ´mes de la sclÃ©rose en plaques. , 2017, , 3-78. | | 0 |
| 22 | The Relationship between Psychosocial Factors and Cognition in Multiple Sclerosis. Behavioural Neurology, 2017, 2017, 1-6. | 1.1 | 11 |
| 23 | A new focal model resembling features of cortical pathology of the progressive forms of multiple sclerosis: Influence of innate immunity. Brain, Behavior, and Immunity, 2018, 69, 515-531. | 2.0 | 25 |
| 24 | Cognition in multiple sclerosis. Neurology, 2018, 90, 278-288. | 1.5 | 384 |
| 25 | Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis. Journal of the Neurological Sciences, 2018, 385, 39-44. | 0.3 | 12 |
| 26 | Improved cognitive outcomes in patients with relapsingâ€“remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Multiple Sclerosis Journal, 2018, 24, 795-804. | 1.4 | 37 |
| 27 | The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 196-204. | 1.4 | 60 |
| 28 | Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. Multiple Sclerosis Journal, 2018, 24, 1883-1891. | 1.4 | 2 |
| 29 | The Rationale for Monitoring Cognitive Function in Multiple Sclerosis: Practical Issues for Clinicians. The Open Neurology Journal, 2018, 12, 31-40. | 0.4 | 17 |
| 30 | Recommendations for cognitive screening and management in multiple sclerosis care. Multiple Sclerosis Journal, 2018, 24, 1665-1680. | 1.4 | 265 |
| 31 | Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study. Multiple Sclerosis and Related Disorders, 2018, 23, 83-87. | 0.9 | 9 |
| 32 | Why Is Cognitive Impairment Present in Multiple Sclerosis? Insights from Functional MRI. Radiology, 2018, 288, 552-553. | 3.6 | 2 |
| 33 | Cognition During and After Multiple Sclerosis Relapse as Assessed With the Brief International Cognitive Assessment for Multiple Sclerosis. Scientific Reports, 2018, 8, 8169. | 1.6 | 30 |
| 34 | A decline in cognitive function should lead to a change in disease-modifying therapy â€“ Yes. Multiple Sclerosis Journal, 2018, 24, 1681-1682. | 1.4 | 9 |
| 35 | Dynamic modular-level alterations of structural-functional coupling in clinically isolated syndrome. Brain, 2019, 142, 3428-3439. | 3.7 | 40 |
| 36 | Distinctive Pattern of Cognitive Disorders During Multiple Sclerosis Relapse and Recovery Based on Computerized CANTAB Tests. Frontiers in Neurology, 2019, 10, 572. | 1.1 | 12 |
| 37 | Cognitive Profiles of Aging in Multiple Sclerosis. Frontiers in Aging Neuroscience, 2019, 11, 105. | 1.7 | 43 |

| # | Article | IF | Citations |
|---|---|---|---|
| 38 | Validity of a multi-domain computerized cognitive assessment battery for patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 30, 154-162. | 0.9 | 24 |
| 39 | Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1781-1790. | 1.4 | 129 |
| 40 | A Videogame-Based Digital Therapeutic to Improve Processing Speed in People with Multiple Sclerosis: A Feasibility Study. Neurology and Therapy, 2019, 8, 135-145. | 1.4 | 31 |
| 41 | Older age, higher perceived disability and depressive symptoms predict the amount and severity of work-related difficulties in persons with multiple sclerosis. Disability and Rehabilitation, 2019, 41, 2255-2263. | 0.9 | 6 |
| 42 | Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 109-113. | 1.4 | 10 |
| 43 | Ecological impact of isolated cognitive relapses in MS. Multiple Sclerosis Journal, 2020, 26, 114-117. | 1.4 | 15 |
| 44 | Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. Journal of Neurology, 2020, 267, 308-316. | 1.8 | 12 |
| 45 | Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. Multiple Sclerosis Journal, 2020, 26, 1938-1947. | 1.4 | 18 |
| 46 | Research on Cognition Disorders. , 2020, , . | | 0 |
| 47 | Montreal cognitive assessment for evaluating cognitive impairment in multiple sclerosis: a systematic review. Acta Neurologica Belgica, 2020, 120, 1307-1321. | 0.5 | 16 |
| 48 | Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurology, The, 2020, 19, 860-871. | 4.9 | 302 |
| 49 | Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Canadian Journal of Neurological Sciences, 2020, 47, 437-455. | 0.3 | 63 |
| 50 | COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination. Brain Sciences, 2020, 10, 345. | 1.1 | 38 |
| 51 | Baseline cerebral metabolism predicts fatigue and cognition in Multiple Sclerosis patients. NeuroImage: Clinical, 2020, 27, 102281. | 1.4 | 8 |
| 52 | Recovery of cognitive function after relapse in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 71-78. | 1.4 | 38 |
| 53 | A novel in-home digital treatment to improve processing speed in people with multiple sclerosis: A pilot study. Multiple Sclerosis Journal, 2021, 27, 778-789. | 1.4 | 21 |
| 54 | Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses. Multiple Sclerosis Journal, 2021, 27, 1077-1087. | 1.4 | 18 |
| 55 | Linking Cognitive Impairment to Neuroinflammation in Multiple Sclerosis using neuroimaging tools. Multiple Sclerosis and Related Disorders, 2021, 47, 102622. | 0.9 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 56 | Smartphone-based symbol-digit modalities test reliably captures brain damage in multiple sclerosis. Npj Digital Medicine, 2021, 4, 36. | 5.7 | 28 |
| 57 | Cognition in acute relapses: A psychometric evaluation and its correlation with event-related potential, P300 in multiple sclerosis. Applied Neuropsychology Adult, 2022, 29, 1552-1561. | 0.7 | 2 |
| 58 | A Randomized Computer-Assisted Rehabilitation Trial of Attention in Pediatric Multiple Sclerosis: A Post Hoc Analysis. Brain Sciences, 2021, 11, 637. | 1.1 | 2 |
| 59 | Cognitive dysfunction and fatigue during relapses: Taking a better look. Multiple Sclerosis Journal, 2021, 27, 981-982. | 1.4 | 0 |
| 60 | Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapyâ€"Kynurenines Are Important Players. Molecules, 2021, 26, 3423. | 1.7 | 20 |
| 61 | Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of life. Multiple Sclerosis and Related Disorders, 2021, 52, 102977. | 0.9 | 2 |
| 62 | Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Multiple Sclerosis Journal, 2022, 28, 790-800. | 1.4 | 13 |
| 63 | Do isolated cognitive relapses exist? Yes. Multiple Sclerosis Journal, 2021, 27, 1486-1487. | 1.4 | 2 |
| 64 | Do isolated cognitive relapses exist? Commentary. Multiple Sclerosis Journal, 2021, 27, 1489-1490. | 1.4 | 3 |
| 65 | Do isolated cognitive relapses exist? â€“ No. Multiple Sclerosis Journal, 2021, 27, 1488-1489. | 1.4 | 4 |
| 66 | Effects of 4-week mindfulness training versus adaptive cognitive training on processing speed and working memory in multiple sclerosis.. Neuropsychology, 2020, 34, 591-604. | 1.0 | 17 |
| 68 | Siponimod and Cognition in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 96, e376-e386. | 1.5 | 64 |
| 69 | The BICAMS Battery for Assessment of Lithuanian-Speaking Multiple Sclerosis Patients: Relationship with Age, Education, Disease Disability, and Duration. Medical Science Monitor, 2015, 21, 3853-3859. | 0.5 | 41 |
| 70 | Neuroimaging and genetic correlates of cognitive dysfunction in multiple sclerosis. Psychiatria Polska, 2015, 49, 897-910. | 0.2 | 3 |
| 71 | Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology. Multiple Sclerosis Journal, 2022, 28, 1101-1111. | 1.4 | 23 |
| 72 | Cognitive impairment. , 2017, , 91-96. | | 0 |
| 73 | Cognitive Research on Early Multiple Sclerosis. , 2020, , 189-205. | | 0 |
| 74 | Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse. Annals of Neurology, 2022, 91, 417-423. | 2.8 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 75 | The efficacy of speed of processing training for improving processing speed in individuals with multiple sclerosis: a randomized clinical trial. Journal of Neurology, 2022, 269, 3614-3624. | 1.8 | 2 |
| 76 | Real-life evidence of treatment with alemtuzumab in patients diagnosed with relapsing-remitting multiple sclerosis in Colombia. Multiple Sclerosis and Related Disorders, 2022, 61, 103780. | 0.9 | 6 |
| 78 | Neuroscience from the comfort of your home: Repeated, self-administered wireless dry EEG measures brain function with high fidelity. Frontiers in Digital Health, 0, 4, . | 1.5 | 5 |
| 79 | Cognitive Relapse in Multiple Sclerosis: New Findings and Directions for Future Research. NeuroSci, 2022, 3, 510-520. | 0.4 | 2 |
| 80 | Regular monitoring of cognitive functions in multiple sclerosis. Neurologie Pro Praxi, 2022, 23, 400-405. | 0.0 | 0 |
| 81 | Are we ready to define cognitive worsening in MS? How different cutoffs detect future cognitive worsening after six years of follow-up. Multiple Sclerosis and Related Disorders, 2023, 69, 104402. | 0.9 | 0 |
| 82 | Capturing cognitive changes in multiple sclerosis by performance-based functional and virtual reality assessments. Annals of Physical and Rehabilitation Medicine, 2023, 66, 101677. | 1.1 | 3 |
| 83 | The TRACK-MS Test Battery: A Very Brief Tool to Track Multiple Sclerosis-Related Cognitive Impairment. Biomedicines, 2022, 10, 2975. | 1.4 | 5 |
| 84 | Importance of Identifying Cognitive Impairment in Multiple Sclerosis. Canadian Journal of Neurological Sciences, 2023, 50, 813-819. | 0.3 | 0 |